Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates
Seminars in Liver Disease · 2026-03 · 46 (01) · 051-062
DOI: 10.1055/a-2779-4984 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, online erschienen am 24.02.2026. Verfasst von Kelley Weinfurtner und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, United States. Hauptthemen laut MEDLINE: Liver Neoplasms. Die Arbeit nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VA, NIH HHS.
Abstract (Originalsprache)
Primary liver cancer remains a global health challenge due to rising incidence, limited curative options, and poor overall survival. Poor outcomes stem from tumor heterogeneity, limited efficacy of current therapies, and comorbid chronic liver disease. Despite recent advances in immunotherapy and combination treatments, response rates remain low, and predictive biomarkers are lacking. As a result, there is an urgent need for preclinical models that capture the molecular, cellular, and immune landscape of primary liver cancer. This review discusses the strengths and limitations of patient-derived models of liver cancer, including two-dimensional patient-derived cell lines (PDCL), three-dimensional (3D) patient-derived tumor organoids (PDTOs), and patient-derived xenografts (PDXs). While PDCLs and PDTOs enable high throughput studies, they lack a representative tumor microenvironment. PDXs, including PDXs in animals with humanized immune systems, may more effectively mimic tumor–environment interactions but are costly, complex, and still contain mouse stromal cells. Ex vivo tissue culture preserves tissue structure and cell–cell interactions in an immunocompetent environment; however, short duration of viable culture limits broader application. Continued innovation in the development of multicellular three-dimensional culture systems and in vivo humanization strategies will play a critical role in enabling the development of more personalized and effective therapies for primary liver cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
- Department of the Radiologic Sciences, Penn Image-Guided Interventions Lab, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
- Drexel University College of Medicine, Drexel University, Philadelphia, Pennsylvania, United States.
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, Pennsylvania, United States.
- Division of Interventional Radiology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.
- Division of Gastroenterology, Corporal Michael J Crescenz VA Medical Center, Philadelphia, Pennsylvania, United States.
Förderung
- VA
- NIH HHS
Zitieren
APA
Weinfurtner, K., Amin, R., Skuli, N., Gade, T. P., & Kaplan, D. E. (2026). Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates. Seminars in Liver Disease, 46(01), 051-062. https://doi.org/10.1055/a-2779-4984
Vancouver
Weinfurtner K, Amin R, Skuli N, Gade TP, Kaplan DE. Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates. Seminars in Liver Disease. 2026;46(01):051-062. doi:10.1055/a-2779-4984
BibTeX
@article{Weinfurtner2026,
author = {Weinfurtner, Kelley and Amin, Rudra and Skuli, Nicolas and Gade, Terence P and Kaplan, David E},
title = {Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates},
journal = {Seminars in Liver Disease},
year = {2026},
volume = {46},
number = {01},
pages = {051--062},
doi = {10.1055/a-2779-4984}
}
EUVIMED